ReviewCurrent cardiology reports2025
Microplastics and Cardiovascular Disease: Should Clinicians Be Paying Attention?
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide clinicians with a concise introduction of microplastics potential role as a cardiovascular risk factor. RECENT
findingsMicroplastics have been identified in human cardiovascular tissues. In vitro and animal-based studies associate microplastics presence with increased oxidative stress, endothelial dysfunction, platelet aggregation disruption, and low-grade inflammation. Small human studies report associations between intraplaque or circulating microplastics and cardiovascular outcomes. However, these signals are associative, method-dependent, and vulnerable to exposure misclassification, co-pollutant confounding, contamination, and heterogeneous analytics. Microplastics are pervasive and biologically plausible as a cardiovascular risk factor, supported by growing in-vitro evidence and incipient human association studies. Cohesive population-level measures to curb MP pollution should be embedded within policies addressing broader environmental cardiovascular risk factors. For clinicians, it remains premature to recommend personal-level mitigation strategies, and MPs are best regarded as an emerging exposure within the patient's exposome that warrants awareness and further rigorous studies.
Indexed as
Identifiers
41307802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.